MIRUM PHARMACEUTICALS INC (MIRM) Stock Price, Quote, News and Overview
NASDAQ:MIRM - Nasdaq - US6047491013 - Common Stock - Currency: USD
MIRM Quote, Performance and Key Statistics
52.02
+0.34 (+0.66%)
The current stock price of MIRM is 52.02 USD. In the past month the price increased by 3.42%. In the past year, price increased by 32.1%.
MIRM Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.43 | 344.84B | ||
| AMGN | AMGEN INC | 14.3 | 159.64B | ||
| GILD | GILEAD SCIENCES INC | 14.62 | 140.79B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.67B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.25 | 60.34B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 52.39B | ||
| ARGX | ARGENX SE - ADR | 72.69 | 41.24B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.68 | 32.36B | ||
| BNTX | BIONTECH SE-ADR | N/A | 25.80B | ||
| INSM | INSMED INC | N/A | 20.62B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 20.10B | ||
| BIIB | BIOGEN INC | 8.24 | 19.33B |
Related stock screener links
About MIRM
Company Profile
Mirum Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Foster City, California and currently employs 322 full-time employees. The company went IPO on 2019-07-18. The firm is focused on the treatment of rare diseases affecting children and adults. The company has three medicines: LIVMARLI (maralixibat) oral solution (Livmarli), Cholbam (cholic acid) capsules, and Chenodal or Ctexli (chenodiol) tablets. Livmarli is an orally administered, minimally-absorbed ileal bile acid transporter (IBAT) inhibitor (IBATi) that is used for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS) in the United States and various other countries and for cholestatic pruritus in patient with progressive familial intrahepatic cholestasis (PFIC) in the United States. Cholbam is used for the treatment of bile acid synthesis disorders due to single enzyme deficiencies and adjunctive treatment of peroxisomal disorders. The firm is also advancing its product candidate, volixibat, for the treatment of adult patients with cholestatic liver diseases.
Company Info
MIRUM PHARMACEUTICALS INC
989 East Hillsdale Boulevard, Suite 300
Foster City CALIFORNIA 94404 US
CEO: Christopher Peetz
Employees: 322
Phone: 16506674085
MIRUM PHARMACEUTICALS INC / MIRM FAQ
What is the stock price of MIRUM PHARMACEUTICALS INC today?
The current stock price of MIRM is 52.02 USD. The price increased by 0.66% in the last trading session.
What is the ticker symbol for MIRUM PHARMACEUTICALS INC stock?
The exchange symbol of MIRUM PHARMACEUTICALS INC is MIRM and it is listed on the Nasdaq exchange.
On which exchange is MIRM stock listed?
MIRM stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for MIRUM PHARMACEUTICALS INC stock?
16 analysts have analysed MIRM and the average price target is 71.74 USD. This implies a price increase of 37.91% is expected in the next year compared to the current price of 52.02. Check the MIRUM PHARMACEUTICALS INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is MIRUM PHARMACEUTICALS INC worth?
MIRUM PHARMACEUTICALS INC (MIRM) has a market capitalization of 2.58B USD. This makes MIRM a Mid Cap stock.
How many employees does MIRUM PHARMACEUTICALS INC have?
MIRUM PHARMACEUTICALS INC (MIRM) currently has 322 employees.
What are the support and resistance levels for MIRUM PHARMACEUTICALS INC (MIRM) stock?
MIRUM PHARMACEUTICALS INC (MIRM) has a support level at 51.92 and a resistance level at 52.06. Check the full technical report for a detailed analysis of MIRM support and resistance levels.
Is MIRUM PHARMACEUTICALS INC (MIRM) expected to grow?
The Revenue of MIRUM PHARMACEUTICALS INC (MIRM) is expected to grow by 35.06% in the next year. Check the estimates tab for more information on the MIRM EPS, Sales, EBIT and EBITDA future analyst estimates.
Should I buy MIRUM PHARMACEUTICALS INC (MIRM) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of MIRM, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of MIRM, evaluating the profitability, health, valuation and growth aspects
- MIRUM PHARMACEUTICALS INC (MIRM) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- MIRUM PHARMACEUTICALS INC (MIRM) Sales and EPS estimates to see what analysts future expectations are.
- MIRUM PHARMACEUTICALS INC (MIRM) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- MIRUM PHARMACEUTICALS INC (MIRM) Insider and Institutional Ownership to learn about the owners and their transactions.
- MIRUM PHARMACEUTICALS INC (MIRM) Stock Chart to make your own analysis
- MIRUM PHARMACEUTICALS INC (MIRM) Latest news and press-releases to stay up to date.
Does MIRUM PHARMACEUTICALS INC (MIRM) stock pay dividends?
MIRM does not pay a dividend.
When does MIRUM PHARMACEUTICALS INC (MIRM) report earnings?
MIRUM PHARMACEUTICALS INC (MIRM) will report earnings on 2025-08-06, after the market close.
What is the Price/Earnings (PE) ratio of MIRUM PHARMACEUTICALS INC (MIRM)?
MIRUM PHARMACEUTICALS INC (MIRM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.61).
What is the Short Interest ratio of MIRUM PHARMACEUTICALS INC (MIRM) stock?
The outstanding short interest for MIRUM PHARMACEUTICALS INC (MIRM) is 15.83% of its float. Check the ownership tab for more information on the MIRM short interest.
MIRM Technical Analysis
ChartMill assigns a technical rating of 10 / 10 to MIRM. When comparing the yearly performance of all stocks, MIRM is one of the better performing stocks in the market, outperforming 85.32% of all stocks.
MIRM Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to MIRM. Both the profitability and financial health of MIRM have multiple concerns.
MIRM Financial Highlights
Over the last trailing twelve months MIRM reported a non-GAAP Earnings per Share(EPS) of -1.61. The EPS increased by 56.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -11.2% | ||
| ROE | -33.16% | ||
| Debt/Equity | 1.32 |
MIRM Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to MIRM. The Buy consensus is the average rating of analysts ratings from 16 analysts.
For the next year, analysts expect an EPS growth of 38.73% and a revenue growth 35.06% for MIRM